Evidence map›Paper›PMID 30708086›Full record

ArticleJournal of microbiological methods2019

A multiplexed, indirect enzyme-linked immunoassay for the detection and differentiation of E. coli from other Enterobacteriaceae and P. aeruginosa from other glucose non-fermenters.

N Jackson, T Z Wu, S Adams-Sapper, T Satoorian, M Geisberg, N Murthy, L Lee, L W Riley

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of microbiological methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

N JacksonSchool of Public Health, Division of Infectious Disease and Vaccinology, University of California, Berkeley, CA 94720, USA.
T Z WuSchool of Public Health, Division of Infectious Disease and Vaccinology, University of California, Berkeley, CA 94720, USA.
S Adams-SapperSchool of Public Health, Division of Infectious Disease and Vaccinology, University of California, Berkeley, CA 94720, USA.
T SatoorianSilver Lake Research Corporation, Azusa, CA 91702, USA.
M GeisbergSilver Lake Research Corporation, Azusa, CA 91702, USA.
N MurthySchool of Public Health, Division of Infectious Disease and Vaccinology, University of California, Berkeley, CA 94720, USA.
L LeeSchool of Public Health, Division of Infectious Disease and Vaccinology, University of California, Berkeley, CA 94720, USA.
L W RileySchool of Public Health, Division of Infectious Disease and Vaccinology, University of California, Berkeley, CA 94720, USA. Electronic address: lwriley@berkeley.edu.
University of California, Berkeley · USSilver Lake Research (United States) · USBerkeley Public Health Division · US

Funding

Consortium for drug-resistant Gram-negative pathogen detectionR01AI117064 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LEE, LUKE P., MURTHY, NIREN · 2015 to 2019
$5.7M
Maltodextrin based antibioticsR21AI098799 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI MURTHY, NIREN · 2012 to 2013
$436k
Maltose Targeted AntibioticsR21AI119115 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI MURTHY, NIREN, RILEY, LEE W · 2015 to 2016
$414k
NIAID NIH HHS R01 AI117064NIAID NIH HHS R21 AI098799NIAID NIH HHS R21 AI119115
6 · The paper itself

Abstract

Gram-negative bacteria (GNB) are important causes of community (CA) and hospital (HA)- associated infections. Here we describe the development of an indirect ELISA (I-ELISA), which can be used to detect and differentiate the Enterobacteriaceae Escherichia coli, and glucose non-fermenter Pseudomonas aeruginosa from other GNB species. The I-ELISA utilizes six antibodies for bacterial speciation, which were grouped according to their bacterial targets; Enterobacteriaceae (SL-EntA and CH1810 mAb), Escherichia coli (SL-EcA and 6103-46 mAb), Pseudomonas aeruginosa (SL-PaA and SL-PaB). The six, anti-GNB antibodies were first screened against a panel of well-characterized clinical GNB isolates to optimize assay conditions and to determine individual antibody sensitivity and specificity. When tested against a diverse, blinded panel of 94 GNB clinical isolates, the I-ELISA exhibited the following sensitivity/specificity for each target: Enterobacteriaceae (94.4%/95%), E. coli (82.6%/88.7%), P. aeruginosa (83.3%/96%). An I-ELISA to detect and differentiate the most common GNB pathogens offers advantage in terms of simplicity over diagnostic tests currently used in most clinical settings.

Indexed as

Enzyme-Linked Immunosorbent AssayAntibodies, BacterialEnterobacteriaceaeEscherichia coliFermentationGlucoseGram-Negative Bacterial InfectionsHumansLatex Fixation TestsMicrobial Sensitivity TestsPseudomonas aeruginosaSensitivity and SpecificityAntibodies, BacterialGlucoseBacterial detectionELISAGram-negative bacteriaLatex agglutination test

Identifiers

PMID30708086
PMCPMC11675078
OpenAlexW2914786942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.